Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC

PURPOSE: We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. It expands the known spectrum of complications of Crizotinib. METHODS: Clinical case report. RESULTS: Multiple aseptic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Daniel, Decker, Miriam, Schuster, Michael, Folz, Sara, Stürmer, Carsten Johannes, Lutz, Manfred P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557187/
https://www.ncbi.nlm.nih.gov/pubmed/34373943
http://dx.doi.org/10.1007/s00432-021-03664-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557187/
https://www.ncbi.nlm.nih.gov/pubmed/34373943
http://dx.doi.org/10.1007/s00432-021-03664-w

Ejemplares similares